Fox Corp Class B vs GSK plc — how do they compare? Fox Corp Class B trades at $55.42 (market cap $24.58B), while GSK plc trades at $50.62 (market cap $102.60B). The key difference: GSK plc is far larger — about 4.2× Fox Corp Class B's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| FOX | GSK | |
|---|---|---|
Market Cap | $24.58B | $102.60B |
Sector | Media | Health |
52-Week High | $67.76 | $61.18 |
52-Week Low | $44.39 | $38.22 |
Enterprise Value | $27.94B | $123.04B |
Dividend Yield | 1.05% | 3.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →